U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096453) titled 'CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients' on July 24.
Brief Summary: The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Kidney Transplant; Complications
CMV
Intervention:
DRUG: Cytogam
Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduce...